建立從胸腔積液肺腺癌在51歲的日本女性。LC-2/ad細(xì)胞呈上皮狀，傾向于形成小圓丘。免疫細(xì)胞化學(xué)染色顯示CEA和細(xì)胞角蛋白陽(yáng)性，包括細(xì)胞角蛋白No.18。LC-2/ad在體外產(chǎn)生至少兩種功能活性胰蛋白酶抑制劑和幾種蛋白酶經(jīng)無(wú)支原體/STR鑒定入庫(kù)。

動(dòng)物種別：日本女性，51歲

組織來(lái)源：胸腔積液，肺腺癌

形態(tài)：上皮細(xì)胞樣，貼壁生長(zhǎng)

培養(yǎng)基配方：

45%1640(MD0200)+45%F12(MD0500)+10%胎牛血清(SD0200)+SP（SD0008）+

G/A (SD0038)

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

凍存條件：基礎(chǔ)培養(yǎng)基+5%DMSO+20%FBS(SD0200)

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=8291444; DOI=10.1111/j.1440-1827.1993.tb03232.x

Kataoka H., Itoh H., Seguchi K., Koono M.

Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing alpha 1-antitrypsin in vitro.

Acta Pathol. Jpn. 43:566-573(1993)

PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R

Kataoka H., Seguchi K., Inoue T., Koono M.

Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines.

FEBS Lett. 328:291-295(1993)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331

Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Cancer Res. 65:7276-7282(2005)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=22313637; DOI=10.4161/cbt.19238

Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Cancer Biol. Ther. 13:369-378(2012)

PubMed=23154560; DOI=10.1097/JTO.0b013e3182721ed1

Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T., Sakatani T., Oguni S., Tamura T., Kataoka H., Endo S., Murakami Y., Aburatani H., Fukayama M., Niki T.

Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.

J. Thorac. Oncol. 7:1872-1876(2012)

PubMed=23578175; DOI=10.1111/cas.12175

Suzuki M., Makinoshima H., Matsumoto S., Suzuki A., Mimaki S., Matsushima K., Yoh K., Goto K., Suzuki Y., Ishii G., Ochiai A., Tsuta K., Shibata T., Kohno T., Esumi H., Tsuchihara K.

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.

Cancer Sci. 104:896-903(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)